澳门广东会(中国·VIP认证)股份有限公司
澳门广东会
TaiGen Biotechnology
0
0
0
About
Overview
Steering Committee
Career
Management Team
Milestones
Board of Directors
About Us
TaiGen is a discovery-based and market-focused pharmaceutical company engaging in the development of novel therapeutics for infectious diseases and other indications with high degree of unmet medical needs.
R&D Center
Pipeline
R&D Progress
Antibiotic
Taigexyn®
Influenza Antiviral
TG-1000
HCV Antiviral
Furaprevir
Stem Cell Mobilizer
Burixafor
Research
R&D Center
TaiGen’s dedicated team of professional scientists perform cutting edge research in drug discovery to advance programs efficiently. Our pipeline of anti-infective & anti-inflammatory programs are the fruits of both internal research as well as in-licensed programs.
News
News
Investors
Investors
Financial Information
Material Information
Material Information
Shareholders' Information
Shareholders' Information
Corporate Governance
Investor FAQs
Investors
Communicating with investors, cultivating long-term investor relations and highlighting corporate’s value.
Business & Partnership
ESG
Contact Us
Home
繁中
Material Information
Material Information
All Year
2024Year
Date
Material Information
2024-06-26
公告本公司取得會計師112年內部控制專案審查報告
2024-05-30
公告本公司113年度股東常會重要決議事項
2024-05-13
公告本公司更換簽證會計師
2024-05-03
公告113年第1季財務報告董事會召開日期
2024-04-17
代子公司澳门广东会科技股份有限公司、太景醫藥研發(北京) 有限公司公告抗流感病毒新藥(TG-1000)於中國大陸之第三期臨 床試驗主要評估指標的解盲結果(Top-line Results)
1
2
Next
Home
Investors
Material Information
网站首页
澳门广东会